Biogen (BIIB) had its price target raised by Rothschild & Co Redburn from $150.00 to $180.00. They now have a "neutral" rating on the stock.
Biogen (BIIB) had its price target raised by JPMorgan Chase & Co. from $175.00 to $185.00. They now have a "neutral" rating on the stock.
Jim Cramer Says “I Got to Reopen the File on Biogen” [Yahoo! Finance]
Biogen (BIIB) was upgraded by UBS Group AG from "neutral" to "buy". They now have a $225.00 price target on the stock.
Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio [Yahoo! Finance]